NCT02443623CompletedPhase 4
Vaccinia Vaccination (ACAM2000®) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV)
Emergent BioSolutions1 site in 1 country3,032 target enrollmentStarted: September 1, 2015Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Emergent BioSolutions
- Enrollment
- 3,032
- Locations
- 1
- Primary Endpoint
- Number of Vaccinated Participants With Related Adverse Events
Study Overview
Brief Summary
Objectives:
- To vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).
- To ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data.
Detailed Description
This protocol is being conducted to vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV). The objective of this protocol is to ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data.
Participants will be followed for the duration of the study, an expected average of 90 days as described below in the planned study assessments.
Screening [complete within 14 days before Baseline (Day 0)]:
- Informed consent obtained from prospective donors
- Post-consent information including medical history, smallpox vaccination history, current medications, detailed demographics, BMI, physical exam, vital signs, and assessment for pericarditis/myocarditis symptoms, blood samples will be collected and a baseline EKG (if applicable).
Baseline (Day 0) prior to vaccination:
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Signed written informed consent.
- •Age 18 to
- •Normal and healthy (immune competent) as determined by medical history, physical exam, vital signs and clinical laboratory tests during the screening period.
- •If all lab results for quantitative IgA immunoglobulin level are lower than 15% below normal range, the subject may not proceed further in the screening process.
- •Subject must meet all required subject suitability criteria that pertain to normal source plasma donors.
- •Negative HIV serology during screening period.
- •Subject must have been previously immunized for smallpox, at ≥3 years prior to commencement of screening assessments, and vaccination history must be confirmed by oral or written history and the presence of a visible pathognomonic smallpox vaccination scar.
Exclusion Criteria
- •History of severe related adverse event(s) from previous participation in VA-001 or VA-006 trials or to any smallpox vaccination.
- •The subject, or a household contact or other close/intimate contact of the subject has ANY of the following:
- •Eczema, history of eczema, exfoliative skin conditions, wounds, burns, or other skin conditions at the investigator's discretion.
- •A history of immunodeficiency.
- •Currently or has recently received radiotherapy or chemotherapy, adrenocorticotropic hormone (ACTH), corticosteroids, or immunosuppressive drugs.
- •Eye disease treated with topical steroids.
- •Known or suspected disorders of immunoglobulin synthesis.
- •Leukemia, lymphomas of any type, melanoma, or other malignant neoplasms affecting the bone marrow or lymphatic systems.
- •Has been diagnosed with cancer and who will be undergoing chemotherapy or radiation therapy during the vaccination healing time.
- •Is a transplant recipient (except for corneal transplant).
- •Is pregnant, planning pregnancy or breast feeding (female subjects of childbearing potential must have negative pregnancy test prior to vaccination). Women of child-bearing potential (WOCBP) are temporarily excluded due to COVID.
- •Household or other close/intimate contact(s) under the age of 12 months.
- •History of allergies to phenol, any of the antibiotics listed in the vaccine content, or any other component of ACAM2000 or its diluents.
- •Subjects with kidney disease (except kidney stones).
- •Subjects with abnormal EKG at screening (if applicable). To mitigate the risk of enrolling at risk subjects and potentially jeopardizing subject safety an EKG will be performed prior to vaccination with ACAM2000 smallpox vaccine in all potential subjects ≥50 years old and for all potential subjects <50 with two cardiac risk factors as listed immediately below including; severely or morbidly obese or higher obesity classification (BMI ≥36); high blood pressure; high blood cholesterol; diabetes or high blood sugar; a first degree relative who had a heart condition before the age of 50; and current tobacco smokers.
- •Subject has three or more of the following risk factors:
- •Severely or morbidly obese or higher obesity classification (BMI ≥36)
- •High blood pressure diagnosed by a doctor
- •High blood cholesterol diagnosed by a doctor
- •Diabetes or high blood sugar diagnosed by a doctor
- •A first degree relative (for example, mother, father, brother, sister) who had a heart condition before the age of 50
- •Currently smokes tobacco (cigarettes)
- •Cardiovascular disease or heart condition diagnosed by a doctor at any time in the past, with or without symptoms, including:
- •Arrhythmia
- •Syncope related to cardiac disease
- •Previous myocardial infarction
- •Coronary artery disease
- •Congestive heart failure
- •Cardiomyopathy
- •Stroke or transient ischemic attack
- •Myocarditis
- •Pericarditis
- •Chest pain or shortness of breath with activity (such as climbing stairs), peripheral edema, heart palpitations, dry cough, irregular heartbeat, excessive fatigue, unexplained syncope
- •Other heart conditions being treated by a physician
Arms & Interventions
Single Arm Vaccinated with ACAM2000
Experimental
- To vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).
- To ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data.
Intervention: Vaccination with ACAM2000 (Biological)
Outcomes
Primary Outcomes
Number of Vaccinated Participants With Related Adverse Events
Time Frame: Adverse event data was collected from vaccinated participants through Day 90.
Number of subjects with related AEs up to 90 days after vaccination.
Number of Vaccinated Participants With Serious Adverse Events (SAEs)
Time Frame: Adverse event data was collected from vaccinated participants through Day 90.
Number of subjects with SAEs up to 90 days after vaccination.
Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs)
Time Frame: Adverse event data was collected from vaccinated participants through Day 90.
Number of subjects with AEs including SAEs up to 90 days after vaccination.
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIVSmallpox Vaccine Adverse ReactionNCT01158157Emergent BioSolutions25
Completed
Phase 4
Special Access Program IMVAMUNE®VaccinationNCT03472014Bavarian Nordic22
Unknown
Phase 1
Convalescent Plasma Therapy for COVID-19 PatientsSARS-CoV InfectionNCT04565197Lahore General Hospital20
Completed
Phase 1
Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological MalignanciesHematological MalignanciesNCT00423124AGC Biologics S.p.A.57
Completed
Phase 1
ACAM 3000 MVA at Harvard Medical SchoolSmallpoxNCT00133575National Institute of Allergy and Infectious Diseases (NIAID)72